Physician profile
James T Menges
NPI 1427277300
$7,665.94
in general payments reported to CMS, 2019-2025
22 companies · $2,431 in 2025
The $2,431 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $432 · 2021: $579 · 2022: $892 · 2023: $1,319 · 2024: $1,581 · 2025: $2,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,219 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,218.91 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,775.36 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,073.18 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $992.94 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $975.06 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $679.04 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $392.28 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $336.08 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $289.11 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $187.75 | 2024-2025 | Cobenfy |
| Allergan, INC. | $140.49 | 2020 | |
| Braeburn INC. | $138.70 | 2023-2025 | Brixadi |
| Indivior INC. | $134.90 | 2022-2023 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $117.46 | 2023-2025 | Auvelity |
| Lundbeck LLC | $104.38 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $82.81 | 2021-2023 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $56.72 | 2024-2025 | Zubsolv |
| Avanir Pharmaceuticals, INC. | $53.41 | 2019-2020 | |
| Noven Therapeutics, LLC | $45.97 | 2024 | Secuado, Xelstrym |
| Janssen Biotech, INC. | $28.81 | 2025 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $27.61 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.33 | 2021 | |
| Corium, LLC | $14.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Menges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.